Compares elranatamab with standard combination treatments in relapsed multiple myeloma
Tests elranatamab against combination medicines in adults with myeloma that has returned.
Key facts
- Who runs it
- Pfizer
- Where
- Berlin, Bonn, Cottbus, Freiburg im Breisgau, Hamburg, Hamm, Jena, Nuremberg, Speyer, Stuttgart, and Ulm, GermanySee the 11 sitesAlso in 26 other countries, 265 sites
- Trial code
- Registry title
- MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 492 people, planned
- Started
- 8 Feb 2024
- Expected to end
- 30 Dec 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Elranatamab
- Elotuzumab
- Pomalidomide
- Dexamethasone
- Bortezomib
- Carfilzomib
- Record updated
- 12 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with multiple myeloma that came back or did not respond after 1 to 4 earlier treatments, including an anti-CD38 antibody and lenalidomide.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Multiple myeloma that got worse or did not respond to the last treatment, with disease that can be measured by blood or urine tests. ECOG performance status of 2 or lower.
- Earlier treatment
- Must have had 1 to 4 earlier lines of treatment, including an anti-CD38 antibody and lenalidomide. Cannot have had earlier BCMA-directed or CD3-redirecting therapy.
- Biomarker or test result
- Measurable disease: serum M-protein ≥0.5 g/dL, or urinary M-protein ≥200 mg/24 hours, or serum involved immunoglobulin FLC ≥10 mg/dL with an abnormal kappa to lambda FLC ratio (<0.26 or >1.65).
Main reasons for not taking part
- Smoldering multiple myeloma, plasma cell leukemia, amyloidosis or POEMS syndrome
- Myeloma in the central nervous system
- Stem cell transplant within 12 weeks, or active graft versus host disease
- Active, uncontrolled infection
- Another active cancer within 3 years (with a few exceptions)
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Prior diagnosis of multiple myeloma as defined by International Myeloma Working Group (IMWG) criteria and previously received 1 to 4 prior lines of therapy including prior anti-cluster of differentiation 38 (CD38) antibody and prior lenalidomide
- Documented evidence of progressive disease or failure to achieve a response to last line of therapy per IMWG criteria
- Measurable disease defined as at least 1 of the following: (a) Serum M-protein ≥0.5 g/dL; (b) Urinary M-protein excretion ≥200 mg/24 hours; (c) Serum involved immunoglobulin FLC ≥10 mg/dL AND abnormal serum immunoglobulin kappa to lambda FLC ratio (<0.26 or >1.65)
- Have clinical laboratory values within the specified range
- ECOG (Eastern Cooperative Oncology Group) performance status ≤2
- Not pregnant or breastfeeding and willing to use contraception
Who cannot take part
- Stem cell transplant within 12 weeks prior to enrolment, or active graft versus host disease
- Any other active malignancy within 3 years prior to enrolment (exceptions include, adequately treated basal cell or squamous cell skin cancer, carcinoma in situ)
- Previous treatment with a B cell maturation antigen (BCMA)-directed therapy or CD3-redirecting therapy
- Unable to receive investigator's choice therapy
- Live attenuated vaccine within 4 weeks of the first dose of study intervention
- Administration with an investigational product (e.g. drug or vaccine) within 30 days preceding the first dose of study intervention used in this study
- Polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin abnormalities (POEMS) syndrome
- Any active, uncontrolled bacterial, fungal, or viral infection
- Smoldering multiple myeloma
- Plasma cell leukemia
- Amyloidosis
- Known central nervous system (CNS) involvement or clinical signs of myelomatous meningeal involvement
Where in Germany
Also in 26 other countries, 265 sites
- Vivantes Netzwerk fuer Gesundheit GmbHBerlin, GermanyTaking people
- Universitaetsklinikum Bonn AöRBonn, GermanyTaking people
- Medizinischen Universität Lausitz – Carl ThiemCottbus, GermanyTaking people
- Medical Center- University of FreiburgFreiburg im Breisgau, GermanyTaking people
- Asklepios Kliniken Hamburg GmbHHamburg, GermanyTaking people
- St. Barbara-Klinik Hamm GmbHHamm, GermanyTaking people
- Universitaetsklinikum Jena KöRJena, GermanyTaking people
- Klinikum NuernbergNuremberg, GermanyTaking people
- Diakonissen-Stiftungs-Krankenhaus Speyer gGmbHSpeyer, GermanyTaking people
- Robert Bosch Krankenhaus GmbHStuttgart, GermanyTaking people
- Universitaetsklinikum Ulm AoRUlm, GermanyTaking people
About the trial
What the trial wants to find out
The purpose of this study is to learn about the study medicine called elranatamab.This study aims to compare elranatamab to other medicines for the treatment of MM (a type of cancer).
Read full original descriptionShow less
This study is seeking participants who:
* Are 18 years of age or older and have MM. * Have received treatments before for MM. * Have MM that has returned or not responded to their most recent treatment.
Half of the participants will receive elranatamab. The other half of participants will receive a combination therapy selected by the study doctor. The selected combination therapy will include 2 to 3 different medicines commonly used to treat MM.
Elranatamab will be given as a shot under the skin at the study clinic about once a week. This may change to a smaller number of shots later in the study.
The medicines in the combination therapy will be taken by mouth (at home or at the study clinic) AND will be given either as:
* a shot under the skin at the study clinic * through a needle in the vein at the study clinic The number of times these medicines will be taken depends on what combination therapy the study doctor selects.
Participants may continue to receive elranatamab or a combination therapy until their MM is no longer responding. The study team will see how each participant is doing with the study treatment during regular visits at the study clinic. The study team will continue to follow-up with participants after study treatment with telephone contacts (or visits).
The study will compare the experiences of people receiving elranatamab to those people receiving a combination therapy. This will help learn about the safety and how effective elranatamab is.
The 2 groups in the trial
- ElranatamabTreatment being tested
Participants will receive elranatamab monotherapy
- Investigator's ChoiceExisting treatment, for comparison
Participants will receive either Elotuzumab, Pomalidomide and Dexamethasone (EPd), or Pomalidomide, Bortezomib and Dexamethasone (PVd), or Carfilzomib and Dexamethasone (Kd)
Treatment: Elotuzumab, Pomalidomide, Dexamethasone, Bortezomib, and Carfilzomib
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
- Official title
- A PHASE 3, OPEN-LABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB, POMALIDOMIDE, DEXAMETHASONE (EPd) OR POMALIDOMIDE, BORTEZOMIB, DEXAMETHASONE (PVd) OR CARFILZOMIB, DEXAMETHASONE (Kd) IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTI-CD38 DIRECTED THERAPY
- Plain-language title
- Compares elranatamab with standard combination treatments in relapsed multiple myelomaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 12 November 2026